Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,751 questions in 147 reviews · Pain, Palliative and Supportive Care

current versions

No studies 361 · 20.6%Ungraded 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Serious adverse events · Adults with chronic neuropathic pain Fentanyl for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	1 study · 258 participants	Very low
Intervention NR Deaths · Adults with chronic neuropathic pain Fentanyl for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	1 study · 258 participants	Very low
Pregabalin vs placebo ‘Substantial benefit’ (at least 50% reduction in pain) · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1874 participants	High
Pregabalin vs placebo Participants experiencing at least 1 adverse event · adults with fibromyalgia enrolled in EERW studies Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 687 participants	High
Pregabalin vs placebo Serious adverse events · adults with fibromyalgia enrolled in EERW studies Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 687 participants	Very low
Pregabalin vs placebo Death · adults with fibromyalgia enrolled in EERW studies Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 687 participants	Very low
Pregabalin vs placebo ‘Substantial benefit’ (PGIC very much improved) · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1869 participants	High
Pregabalin vs placebo ‘Moderate benefit’ (at least 30% reduction in pain) · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1874 participants	High
Pregabalin vs placebo ‘Moderate benefit’ (PGIC much or very much improved) · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1869 participants	High
Pregabalin vs placebo Withdrawals due to lack of efficacy · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1874 participants	High
Pregabalin vs placebo Withdrawals due to adverse events · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	5 studies · 1874 participants	High
Pregabalin vs placebo Serious adverse events · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	3 studies · 1238 participants	Very low
Pregabalin vs placebo Death · adults with fibromyalgia enrolled in studies of classic design Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	6 studies · 3460 participants	Very low
Pregabalin vs placebo Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 687 participants	High
Intervention NR At least 50 % pain relief · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 155 participants	Very low
Intervention NR Patient Global Impression of Change much or very much improved · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Sleep problems (Scale 0 to 21; higher scores indicate more sleep problems) · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 87 participants	Very low
Intervention NR Depression (Scale 0 to 50) · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	3 studies · 207 participants	Very low
Intervention NR Withdrawals due to adverse events · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 155 participants	Very low
Intervention NR Serious adverse events · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	3 studies · 206 participants	Very low
Intervention NR Substantial weight gain · adults with fibromyalgia Antipsychotics for fibromyalgia in adults (2016) · Cochrane	no estimate extracted	2 studies · 155 participants	Very low
Paracetamol 1000 mg vs placebo Pain‐free at 2 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	High
Paracetamol 500 mg to 650 mg vs placebo Pain‐free at 4 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	No studies
Paracetamol 500 mg to 650 mg vs placebo Use of rescue medication · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Low
Paracetamol 500 mg to 650 mg vs placebo Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Low
Paracetamol 500 mg to 650 mg vs placebo Any adverse event · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Low
Paracetamol 500 mg to 650 mg vs placebo Serious adverse events · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol 1000 mg vs placebo Pain‐free at 1 hour · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Paracetamol 1000 mg vs placebo Pain‐free at 4 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Paracetamol 1000 mg vs placebo Use of rescue medication · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Paracetamol 1000 mg vs placebo Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	High
Paracetamol 1000 mg vs placebo Any adverse event · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	High
Paracetamol 1000 mg vs placebo Serious adverse events · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Paracetamol 500 mg to 650 mg vs placebo Pain‐free at 2 hours · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	No studies
Paracetamol 500 mg to 650 mg vs placebo Pain‐free at 1 hour · adults with episodic tension‐type headache Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	No studies
Ketoprofen 25 mg vs placebo Pain‐free at 2 hours · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Low
Ketoprofen 25 mg vs placebo Pain‐free at different time points (1, 4, 24 hours) · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Ketoprofen 25 mg vs placebo Pain‐free or mild pain at 2 hours · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Ketoprofen 25 mg vs placebo Use of rescue medication · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Moderate
Ketoprofen 25 mg vs placebo Any adverse event · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Low
Ketoprofen 25 mg vs placebo Specific adverse events · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Ketoprofen 25 mg vs placebo Serious adverse events · adults with episodic tension‐type headache Ketoprofen for episodic tension‐type headache in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Lack of efficacy withdrawal · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Adverse event withdrawal · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Serious adverse events · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine vs placebo Deaths · adults with chronic neuropathic pain Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (2016) · Cochrane	no estimate extracted	NR	Very low
Dexketoprofen 25 mg plus tramadol 75 mg vs placebo Participants with ≥ 50% pain relief over 6 hours · adults with moderate or severe acute postoperative pain Single fixed‐dose oral dexketoprofen plus tramadol for acute postoperative pain in adults (2016) · Cochrane	no estimate extracted	3 studies · 748 participants	Moderate
Dexketoprofen 25 mg plus tramadol 75 mg vs placebo Median time to use of rescue medication · adults with moderate or severe acute postoperative pain Single fixed‐dose oral dexketoprofen plus tramadol for acute postoperative pain in adults (2016) · Cochrane	no estimate extracted	1 study · 62 participants	Moderate